Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VTX3232 · 2 trials · 2 indications
A TEAE was defined as any adverse event that occurred after initiation of study treatment or any pre-existing adverse event that worsened in severity following initiation of study treatment.
Incidence of AEs and SAEs
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants received placebo orally once daily for 12 weeks and were followed for 30 days after the last dose. |
| VTX3232 30 mg | EXPERIMENTAL | Participants received VTX3232 30 milligrams (mg) orally once daily for 12 weeks and were followed for 30 days after the last dose. |
| Placebo + Semaglutide | ACTIVE_COMPARATOR | Participants received placebo orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
| VTX3232 30 mg + Semaglutide | EXPERIMENTAL | Participants received VTX3232 30 mg orally once daily for 12 weeks and semaglutide administered subcutaneously once weekly for 12 weeks. Semaglutide doses were 0.25 mg during Weeks 0 - 3, 0.5 mg during Weeks 4 - 7 and 1.0 mg during Weeks 8 - 11. Participants were followed for 30 days after the last dose. |
| VTX3232 Dose A | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Placebo |
| VTX3232 30 mg | DRUG | VTX3232 30 mg |
| Placebo in combination with semaglutide | DRUG | Placebo in combination with semaglutide |
| VTX3232 30 mg in combination with semaglutide | DRUG | VTX3232 30 mg in combination with semaglutide |
| VTX3232 | DRUG | Dose A |
Inclusion Criteria: * Participants are male or female ≥ 18 years up to ≤ 80 years of age. * Ability to comply with study requirements. * BMI ≥ 30.0 to ≤ 42.0 kg/m2 at screening. * Stable body weight (± 5%) for at least 3 months prior to screening. * hs-CRP ≥ 2 mg/L at screening. * Hypertension or h...
VTX3232 is an investigational small molecule drug developed by Ventyx Biosciences, Inc. (ticker VTYX). It is being studied in Phase 2 clinical trials for idiopathic Parkinson disease and obesity. VTX3232 is also known as VTX3232 30 mg. It has not been approved by the FDA and remains in clinical development.
VTX3232 is being evaluated as a potential treatment for idiopathic Parkinson disease and obesity. It is not approved for any indication. The clinical program includes a Phase 2a study in Parkinson's disease and a Phase 2a study in obesity, where it is tested alone or in combination with semaglutide.
VTX3232 targets NLRP3, a component of the inflammasome. It acts as an NLRP3 inhibitor. By inhibiting NLRP3, the drug aims to reduce inflammation, which is thought to play a role in conditions such as Parkinson's disease and obesity. This mechanism is under investigation in Phase 2 trials.
VTX3232 is developed by Ventyx Biosciences, Inc., a biopharmaceutical company with the ticker symbol VTYX. Ventyx is responsible for the clinical development of VTX3232, including the Phase 2a trials in Parkinson's disease and obesity.
VTX3232 is in Phase 2 clinical development. It has completed a Phase 2a study in idiopathic Parkinson disease and a Phase 2a study in obesity. The drug is investigational and has not been approved by the FDA for any indication.
VTX3232 has been studied in two completed Phase 2a trials: NCT06771115, a placebo-controlled study of VTX3232 alone or with semaglutide in obesity, and NCT06556173, a Phase 2a study in idiopathic Parkinson disease. Both trials were conducted in the United States.